Tidying up US stomach cancer approvals
A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
Two oncology floats to end the summer break
Bicara and DualityBio will soon test market appetite for new oncology issues.
Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
Amgen packs up in Claudin6
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
ALX has a Chinese challenger
HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.
The month ahead: July’s upcoming events
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
Merck KGaA’s xevinapant gets SMACked down
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
